• 1
    Tsuruo T,Naito M,Tomida A,Fujita N,Mashima T,Sakamoto H,Haga N. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci 2003; 94: 1521.
  • 2
    Teodori E,Dei S,Martelli C,Scapecchi S,Gualtieri F. The functions and structure of ABC transporters: implications for the design of new inhibitors of Pgp and MRP1 to control multidrug resistance (MDR). Curr Drug Targets 2006; 7: 893909.
  • 3
    Szakács G,Paterson JK,Ludwig JA,Boothe-Genthe C,Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006; 5: 21934.
  • 4
    Bellacosa A,Kumar CC,Di Cristofano A,Testa JR. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 2005; 94: 2986.
  • 5
    Kim D,Dan HC,Park S,Yang L,Liu Q,Kaneko S,Ning J,He L,Yang H,Sun M,Nicosia SV,Cheng JQ. AKT/PKB signaling mechanisms in cancer and chemoresistance. Front Biosci 2005; 10: 97587.
  • 6
    Zaffaroni N,Pennati M,Daidone MG. Survivin as a target for new anticancer interventions. J Cell Mol Med 2005; 9: 36072.
  • 7
    Kim S,Kang J,Qiao J,Thomas RP,Evers BM,Chung DH. Phosphatidylinositol 3-kinase inhibition down-regulates survivin and facilitates TRAIL-mediated apoptosis in neuroblastomas. J Pediatr Surg 2004; 39: 51621.
  • 8
    Camenisch TD,McDonald JA. Hyaluronan: is bigger better? Am J Respir Cell Mol Biol 2000; 23: 4313.
  • 9
    Tammi MI,Day AJ,Turley EA. Hyaluronan and homeostasis: a balancing act. J Biol Chem 2002; 277: 45814.
  • 10
    Boregowda RK,Appaiah HN,Siddaiah M,Kumarswamy SB,Sunila S,Kn T,Mortha K,Toole B,Banerjee SD. Expression of Hyaluronan in human tumor progression. J Carcinog 2006; 5: 2.
  • 11
    Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 2004; 4: 52839.
  • 12
    Heldin P. Importance of hyaluronan biosynthesis and degradation in cell differentiation and tumor formation. Braz J Med Biol Res 2003; 36: 96773.
  • 13
    Knudson W,Knudson CB. Overproduction of hyaluronan in tumor stroma. In: AdanyR, ed. Tumor matrix biology. New York: CRC Press, 1995. 5579.
  • 14
    Lokeshwar VB,Rubinowicz D,Schroeder GL,Forgacs E,Minna JD,Block NL,Nadji M,Lokeshwar BL. Stromal and epithelial expression of tumor markers hyaluronic acid and HYAL1 hyaluronidase in prostate cancer. J Biol Chem 2001; 276: 1192232.
  • 15
    Ghatak S,Misra S,Toole BP. Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway. J Biol Chem 2002; 277: 3801320.
  • 16
    Zeng C,Toole BP,Kinney SD,Kuo JW,Stamenkovic I. Inhibition of tumor growth in vivo by hyaluronan oligomers. Int J Cancer 1998; 77: 396401.
  • 17
    Misra S,Ghatak S,Zoltan-Jones A,Toole BP. Regulation of multidrug resistance in cancer cells by hyaluronan. J Biol Chem 2003; 278: 252858.
  • 18
    Misra S,Ghatak S,Toole BP. Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2. J Biol Chem 2005; 280: 203105.
  • 19
    Lopes EC,García MG,Vellon L,Alvarez E,Hajos SE. Correlation between decreased apoptosis and multidrug resistance (MDR) in murine leukemic T cell lines. Leuk Lymphoma 2001; 42: 77587.
  • 20
    Lehne G,De Angelis P,Den Boer M,Rugstad HE. Growth inhibition, cytokinesis failure and apoptosis of multidrug-resistant leukemia cells after treatment with P-glycoprotein inhibitory agents. Leukemia 1999; 13: 76878.
  • 21
    Alaniz L,García MG,Gallo-Rodriguez C,Agusti R,Sterin-Speziale N,Hajos SE,Alvarez E. Hyaluronan oligosaccharides induce cell death through PI3-K/Akt pathway independently of NF-kappaB transcription factor. Glycobiology 2006; 16: 35967.
  • 22
    Gray A,Olsson H,Batty IH,Priganica L,Peter Downes C. Nonradioactive methods for the assay of phosphoinositide 3-kinases and phosphoinositide phosphatases and selective detection of signaling lipids in cell and tissue extracts. Anal Biochem 2003; 313: 23445.
  • 23
    Singleton PA,Dudek SM,Chiang ET,Garcia JG. Regulation of sphingosine 1-phosphate-induced endothelial cytoskeletal rearrangement and barrier enhancement by S1P1 receptor. PI3 kinase. Tiam1/Rac1, and α-actinin. FASEB J 2005; 19: 164656.
  • 24
    García MG,Alaniz L,Lopes EC,Blanco G,Hajos SE,Alvarez E. Inhibition of NF-kappaB activity by BAY 11-7082 increases apoptosis in multidrug resistant leukemic T-cell lines. Leuk Res 2005; 29: 142534.
  • 25
    Bustamante J,Lopes EC,García MG,Di Libero E,Alvarez E,Hajos SE. Disruption of mitochondrial membrane potential during apoptosis induced by PSC833 and CsA in multidrug resistant lymphoid leukemia. Toxicol. Applied. Pharmacol 2004; 199: 4451.
  • 26
    Lopes EC,García M,Benavides F,Shen J,Conti CJ,Alvarez E,Hajos SE. Multidrug resistance modulators PSC 833 and CsA show differential capacity to induce apoptosis in lymphoid leukemia cell lines independently of their MDR phenotype. Leuk Res 2003; 27: 41323.
  • 27
    Bissell MJ,Radisky D. Putting tumours in context. Nat Rev Cancer 2001; 1: 4654.
  • 28
    Baumgartner G,Gomar-Hoss C,Sakr L,Ulsperger E,Wogritsch Ch. The impact of extracellular matrix on the chemoresistance of solid tumors—experimental and clinical results of hyaluronidase as additive to cytostatic chemotherapy. Cancer Lett 1998; 131: 8599.
  • 29
    St Croix B,Man S,Kerbel RS. Reversal of intrinsic and acquired forms of drug resistance by hyaluronidase treatment of solid tumors. Cancer Lett 1998; 131: 3544.
  • 30
    Johnstone RW,Ruefli AA,Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002; 108: 15364.
  • 31
    Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 2005; 5: 87685.
  • 32
    Grossman D,Kim PJ,Schechner JS,Altieri DC. Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci USA 2001; 98: 63540.
  • 33
    Shingu T,Yamada K,Hara N,Moritake K,Osago H,Terashima M,Uemura T,Yamasaki T,Tsuchiya M. Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells. Cancer Res 2003; 63: 40447.
  • 34
    Hu L,Hofmann J,Lu Y,Mills GB,Jaffe RB. Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and invivo ovarian cancer models. Cancer Res 2002; 62: 108792.
  • 35
    Miletti-González KE,Chen S,Muthukumaran N,Saglimbeni GN,Wu X,Yang J,Apolito K,Shih WJ,Hait WN,Rodríguez-Rodríguez L. The CD44 receptor interacts with P-glycoprotein to promote cell migration and invasion in cancer. Cancer Res 2005; 65: 66607.
  • 36
    Tsujimura S,Saito K,Kohno K,Tanaka Y. Fragmented hyaluronan induces transcriptional up-regulation of the multidrug resistance-1 gene in CD4+ T cells. J Biol Chem 2006; 281: 3808997.
  • 37
    Termeer CC,Hennies J,Voith U,Ahrens T,Weiss JM,Prehm P,Simon JC. Oligosaccharides of hyaluronan are potent activators of dendritic cells. J Immunol 2000; 165: 186370.